secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001082554-23-000033
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics Q3 revenue $609.4M (+18% YoY), net income $267.6M
---------------------------------------------------------------------

- Total revenues $609.4M (+18% YoY); net income $267.6M ($5.38 diluted EPS) vs $239.3M ($4.91) Q3 2022.
- Tyvaso DPI sales $205.1M (+225%) drove total Tyvaso $325.8M (+26%); nebulized Tyvaso declined 38% to $120.7M.
- Remodulin $131.1M (+15%), Orenitram $92.0M (+5%), Unituxin $51.3M (+11%).
- R&D expense $84.7M (+28%) from TETON fibrosis studies and organ manufacturing; SG&A $127.6M (+30%).
- CEO cites record quarterly revenue; pipeline data expected in 2025; management reaffirms ~$4B annual run rate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255423000033/0001082554-23-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255423000033/uthr-20231101.htm
  HTML page:      https://secwatch.observer/filing/0001082554-23-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer